Serum Complement Factor H: A Marker for Progression and Outcome Prediction Towards Immunotherapy in Cutaneous Squamous Cell Carcinoma.

Cancers (Basel) · 2025 · PMC12249423 · PMID 40647461

Europe PMC DOI

hedged sentences

0.0816

closest p · 1.6× alpha

0.0816

boldest claim

The sentences

did not reach statistical significancep = 0.0816so close (0.05 < p ≤ 0.1)

Among adv-cSCC patients, those with progressive disease (PD) exhibited higher baseline CFH levels than those achieving clinical benefit (CR, PR, or SD), although this difference did not reach statistical significance (median = 580.6 vs. 319.6 pg/mL; p = 0.0816; Figure 1 B).

also in 111,027 other papers

a clear trendno p-value reported

Pre-Treatment CFH Independently Predicts PFS in adv-cSCC Although baseline CFH levels were not statistically different between adv-cSCC patients with progression compared to those without progression, they showed a clear trend toward higher values in patients with disease progression.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.